ClinicalTrials.Veeva

Menu
U

University of Tennessee Health Science Center | Preventive Medicine

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bevacizumab
Paclitaxel
Doxorubicin Hydrochloride
Ropeginterferon
Cyclophosphamide
Sorafenib Tosylate
Anastrozole
Bosentan
Tamoxifen Citrate
Lyrica

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 99 total trials

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essen...

Active, not recruiting
Essential Thrombocythemia
Drug: Ropeginterferon alfa-2b-njft (P1101)

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV

Active, not recruiting
Polycythemia Vera
Drug: P1101 (Ropeginterferon alfa-2b-njft)
Drug: Ropeginterferon alfa-2b-njft (P1101)

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Active, not recruiting
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Finerenone Placebo

Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments.This study will evaluate the safety and effects of...

Active, not recruiting
Metastatic Uveal Melanoma
Metastatic Ocular Melanoma
Combination Product: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patie...

Active, not recruiting
Hormone-resistant Prostate Cancer
Stage IV Prostate Cancer
Drug: prednisone
Drug: abiraterone

This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profi...

Active, not recruiting
Hemophilia B
Biological: Factor IX (FIX)
Genetic: AAV5-hFIXco-Padua

IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the preven...

Active, not recruiting
Necrotizing Enterocolitis
Drug: IBP-9414
Drug: Placebo

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting
Colorectal Neoplasms
Drug: Eflornithine placebo & sulindac placebo
Drug: Eflornithine plus sulindac

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenan...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab/rHuPH20

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinom...

Enrolling
Endometrial Cancer
Drug: Matching Placebo for selinexor
Drug: Selinexor

Trial sponsors

University of Tennessee logo
National Cancer Institute (NCI) logo
SWOG Cancer Research Network logo
K
The University of Alabama at Birmingham logo
Actelion Pharmaceuticals logo
Alliance for Clinical Trials in Oncology logo
D
G
P

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems